Henry Schein, Inc. (NASDAQ:HSIC) – Stock analysts at Northcoast Research decreased their Q3 2017 EPS estimates for shares of Henry Schein in a note issued to investors on Tuesday. Northcoast Research analyst E. Snyder now expects that the company will earn $0.92 per share for the quarter, down from their prior forecast of $0.93. Northcoast Research currently has a “Buy” rating and a $109.00 target price on the stock. Northcoast Research also issued estimates for Henry Schein’s Q1 2018 earnings at $1.00 EPS, Q2 2018 earnings at $0.99 EPS and Q4 2018 earnings at $1.08 EPS.

Henry Schein (NASDAQ:HSIC) last released its earnings results on Tuesday, August 8th. The company reported $0.88 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.86 by $0.02. The business had revenue of $3.06 billion during the quarter, compared to analyst estimates of $3.05 billion. Henry Schein had a net margin of 4.59% and a return on equity of 19.91%. The company’s revenue for the quarter was up 6.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.82 earnings per share. COPYRIGHT VIOLATION WARNING: “Q3 2017 EPS Estimates for Henry Schein, Inc. (HSIC) Reduced by Analyst” was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/10/04/q3-2017-eps-estimates-for-henry-schein-inc-hsic-reduced-by-analyst.html.

Other equities research analysts have also issued research reports about the company. Credit Suisse Group reissued a “hold” rating and set a $80.00 price target on shares of Henry Schein in a research note on Thursday, July 13th. Zacks Investment Research cut Henry Schein from a “buy” rating to a “hold” rating in a report on Thursday, June 15th. Jefferies Group LLC reaffirmed a “hold” rating and issued a $88.50 price objective on shares of Henry Schein in a research note on Thursday, September 28th. Royal Bank Of Canada began coverage on Henry Schein in a research note on Tuesday, September 19th. They issued a “sector perform” rating and a $91.00 price objective for the company. Finally, Stifel Nicolaus reaffirmed a “hold” rating on shares of Henry Schein in a report on Thursday, July 6th. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating and seven have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $92.85.

Henry Schein (NASDAQ HSIC) opened at 81.58 on Wednesday. The stock has a market capitalization of $12.90 billion, a P/E ratio of 23.84 and a beta of 1.08. Henry Schein has a 1-year low of $73.11 and a 1-year high of $93.50. The stock has a 50 day moving average of $83.79 and a 200 day moving average of $87.65.

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Waldron LP purchased a new stake in Henry Schein in the 1st quarter worth approximately $286,000. Envestnet Asset Management Inc. raised its holdings in Henry Schein by 37.5% in the 1st quarter. Envestnet Asset Management Inc. now owns 6,976 shares of the company’s stock valued at $1,190,000 after acquiring an additional 1,902 shares during the last quarter. Victory Capital Management Inc. raised its holdings in Henry Schein by 16.0% in the 1st quarter. Victory Capital Management Inc. now owns 9,112 shares of the company’s stock valued at $1,549,000 after acquiring an additional 1,256 shares during the last quarter. Cibc World Markets Corp raised its holdings in Henry Schein by 48.8% in the 1st quarter. Cibc World Markets Corp now owns 8,270 shares of the company’s stock valued at $1,406,000 after acquiring an additional 2,711 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd acquired a new position in Henry Schein in the 1st quarter valued at $701,000. 44.52% of the stock is currently owned by institutional investors and hedge funds.

In related news, SVP Paul Rose sold 2,126 shares of the stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $172.51, for a total transaction of $366,756.26. Following the sale, the senior vice president now owns 17,841 shares of the company’s stock, valued at $3,077,750.91. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 1.27% of the stock is owned by corporate insiders.

Henry Schein announced that its board has initiated a stock repurchase program on Monday, September 18th that allows the company to buyback $400.00 million in outstanding shares. This buyback authorization allows the company to buy up to 6.3% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s leadership believes its shares are undervalued.

Henry Schein Company Profile

Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.

Earnings History and Estimates for Henry Schein (NASDAQ:HSIC)

Receive News & Ratings for Henry Schein Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein Inc. and related companies with MarketBeat.com's FREE daily email newsletter.